Research programme: acylfulvene analogues - MGI Pharma
Alternative Names: MGI 4184Latest Information Update: 16 Oct 2007
At a glance
- Originator University of California
- Developer MGI Pharma
- Class
- Mechanism of Action Alkylating agents; Apoptosis stimulants; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 25 Jul 2006 This programme is still in active development
- 05 Dec 2003 Preclinical trials in Cancer in USA (unspecified route)